- Home
- HAYW vs CPRX Comparison
HAYW vs CPRX Comparison
Compare HAYW & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HAYW | CPRX |
|---|---|---|
| Founded | 1925 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.0B |
| IPO Year | 2021 | 2006 |
Fundamental Metrics
Financial Performance| Metric | HAYW | CPRX |
|---|---|---|
| Price | $13.88 | $23.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $19.50 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 2.1M | 1.0M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.93 | ★ 28.24 |
| EPS | 0.68 | ★ 1.68 |
| Revenue | ★ $1,122,155,000.00 | $119,072,803.00 |
| Revenue This Year | $6.22 | $9.20 |
| Revenue Next Year | $5.96 | $10.51 |
| P/E Ratio | $20.04 | ★ $13.51 |
| Revenue Growth | 6.71 | ★ 16.39 |
| 52 Week Low | $11.10 | $19.05 |
| 52 Week High | $17.73 | $26.56 |
Technical Indicators
Market Signals| Indicator | HAYW | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 30.72 | 49.38 |
| Support Level | $13.33 | $22.25 |
| Resistance Level | $16.66 | $24.94 |
| Average True Range (ATR) | 0.45 | 0.66 |
| MACD | -0.09 | -0.12 |
| Stochastic Oscillator | 15.02 | 45.57 |
Price Performance
Historical ComparisonAbout HAYW Hayward Holdings Inc.
Hayward Holdings is a leading manufacturer of energy-efficient swimming pool equipment and pool automation systems. The company offers a wide range of pool equipment, including pumps, filters, heaters, LED lights, and sanitization. Headquartered in Charlotte, North Carolina, the company has around 2,000 full-time employees. Hayward generated approximately $1.1 billion in revenue in 2025.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.